Cargando…

Influence of Spironolactone on Matrix Metalloproteinase-2 in Acute Decompensated Heart Failure

BACKGROUND: Matrix metalloproteinases (MMPs) are a family of enzymes important for the resorption of extracellular matrices, control of vascular remodeling and repair. Increased activity of MMP2 has been demonstrated in heart failure, and in acutely decompensated heart failure (ADHF) a decrease in c...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ferreira, João Pedro, Santos, Mário, Oliveira, José Carlos, Marques, Irene, Bettencourt, Paulo, Carvalho, Henrique
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Sociedade Brasileira de Cardiologia 2015
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4415867/ https://www.ncbi.nlm.nih.gov/pubmed/25993594 http://dx.doi.org/10.5935/abc.20140205

Ejemplares similares

High-Sensitivity Troponin T: A Biomarker for Diuretic Response in Decompensated Heart Failure Patients
por: Ferreira, João Pedro, et al.
Publicado: (2014)

Acute Heart Failure Registry: Risk Assessment Model in Decompensated Heart Failure
por: Delgado, Anne, et al.
Publicado: (2016)

Use, tolerability and compliance of spironolactone in the treatment of heart failure
por: Lachaine, Jean, et al.
Publicado: (2011)

Furosemide and spironolactone doses and hyponatremia in patients with heart failure
por: Velat, Ivan, et al.
Publicado: (2020)

Decompensated heart failure
por: Mangini, Sandrigo, et al.
Publicado: (2013)

Real‐world analysis of acute decompensated heart failure outcomes in Portugal
por: Marques‐Alves, Patrícia, et al.
Publicado: (2020)

Adding High-Dose Spironolactone to Tolvaptan Improves Acute Decompensated Heart Failure Due to Obstructive Hypertrophic Cardiomyopathy and Aortic Stenosis: A Case Report
por: Kajimoto, Katsuya, et al.
Publicado: (2019)

The course of patients with Chagas heart disease during episodes of decompensated heart failure
por: Issa, Victor Sarli, et al.
Publicado: (2021)

Iatrogenic Decompensated Heart Failure
por: Tran, Patrick, et al.
Publicado: (2020)

Infection in Patients with Decompensated Heart Failure: In-Hospital Mortality and Outcome
por: Cardoso, Juliano Novaes, et al.
Publicado: (2018)

Towards a multi‐marker prognostic strategy in acute heart failure: a role for GDF‐15
por: Bettencourt, Paulo, et al.
Publicado: (2018)

Matrix Metalloproteinase 2 as a Pharmacological Target in Heart Failure
por: Gonçalves, Pricila Rodrigues, et al.
Publicado: (2022)

Phenotypes of heart failure with preserved ejection fraction and effect of spironolactone treatment
por: Choy, Manting, et al.
Publicado: (2022)

Acute Decompensated Heart Failure Update
por: Teerlink, John R, et al.
Publicado: (2015)

Multimodality imaging in decompensated heart failure
por: D’Andrea, Antonello, et al.
Publicado: (2023)

Natriuretic Peptide System Activation in Acute Heart Failure Patients with Diabetes
por: Cunha, Filipe M., et al.
Publicado: (2017)

Paradoxical Role of Matrix Metalloproteinases in Liver Injury and Regeneration after Sterile Acute Hepatic Failure
por: Alvarenga, Débora Moreira, et al.
Publicado: (2018)

Cost-Effectiveness Analysis of Patiromer and Spironolactone Therapy in Heart Failure Patients with Hyperkalemia
por: Bounthavong, Mark, et al.
Publicado: (2018)

The Utilization of Spironolactone in Heart Failure Patients at a Tertiary Hospital in Saudi Arabia
por: Alotaibi, Abdulmalik S, et al.
Publicado: (2020)

Prognosis and risk stratification in patients with decompensated heart failure receiving inotropic therapy
por: Gomes, Clara, et al.
Publicado: (2018)

Implication on the prognosis according to the cause of heart failure decompensation
por: MB Silva, Pedro Gabriel, et al.
Publicado: (2015)

Association between matrix metalloproteinase‐9 and worsening heart failure events in patients with chronic heart failure
por: Morishita, Tetsuji, et al.
Publicado: (2017)

Prolargin and matrix metalloproteinase‐2 in heart failure after heart transplantation and their association with haemodynamics
por: Ahmed, Abdulla, et al.
Publicado: (2019)

Influence of renal dysfunction on inhospital morbidity and mortality of patients with decompensated heart failure
por: Rocha, RM, et al.
Publicado: (2005)

Prevalence and characteristics of sleep apnoea in patients with stable heart failure: Results from a heart failure clinic
por: Ferreira, Susana, et al.
Publicado: (2010)

Heart failure and health related quality of life
por: Coelho, Rui, et al.
Publicado: (2005)

Matrix Metalloproteinase-2 Polymorphisms in Chronic Heart Failure: Relationship with Susceptibility and Long-Term Survival
por: Beber, Ana Rubia C., et al.
Publicado: (2016)

Enlarging Red Blood Cell Distribution Width During Hospitalization Identifies a Very High-Risk Subset of Acutely Decompensated Heart Failure Patients and Adds Valuable Prognostic Information on Top of Hemoconcentration
por: Ferreira, João Pedro, et al.
Publicado: (2016)

Variants of the Matrix Metalloproteinase-2 but not the Matrix Metalloproteinase-9 genes significantly influence functional outcome after stroke
por: Manso, Helena, et al.
Publicado: (2010)

Clinical efficacy of a benazepril and spironolactone combination in dogs with congestive heart failure due to myxomatous mitral valve disease: The BEnazepril Spironolactone STudy (BESST)
por: Coffman, Melissa, et al.
Publicado: (2021)

Hospital Variation of Spironolactone Use in Patients Hospitalized for Heart Failure in China—The China PEACE Retrospective Heart Failure Study
por: Yu, Yuan, et al.
Publicado: (2022)

The Role of Ultrafiltration in Patients with Decompensated Heart Failure
por: Kamath, Sandeep A.
Publicado: (2010)

Management of Mechanical Ventilation in Decompensated Heart Failure
por: Kuhn, Brooks T., et al.
Publicado: (2016)

Impact of environmental factors on heart failure decompensations
por: Escolar, Vanessa, et al.
Publicado: (2019)

Iron Deficiency in Acute Decompensated Heart Failure
por: Beale, Anna, et al.
Publicado: (2019)

Hypoalbuminemia in Patients with Acute Decompensated Heart Failure
por: Imamura, Teruhiko
Publicado: (2019)

Dynamics of growth differentiation factor 15 in acute heart failure
por: Lourenço, Patrícia, et al.
Publicado: (2021)

Spironolactone use is associated with improved outcomes in heart failure with mid‐range ejection fraction
por: Enzan, Nobuyuki, et al.
Publicado: (2020)

Spotlight on Spironolactone Oral Suspension for the Treatment of Heart Failure: Focus on Patient Selection and Perspectives
por: Manolis, Antonis A, et al.
Publicado: (2019)

Targeting efficacy of spironolactone in patients with heart failure with preserved ejection fraction: the TOPCAT study
por: Zhou, Hui‐min, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_o3q1slcmu914chbqdcolp8o4fn